Bio-IT World February 26, 2025
Stellaromics commercializes their 3D spatial biology platform, Pyxa; Latent Labs’ AI platform shows promising potential to open new paths to personalized medicines; and more.
$200M: Series C for Rare Muscle Disease Treatment
Abcuro has closed a $200 million Series C financing round. The company will use the money in part for a Phase II/III MUSCLE clinical trial for ulviprubart, an antibody against killer cell lectin-like receptor G1 (KLRG1), to treat a rare, chronic inflammatory muscle disease called inclusion body myositis. The company is planning to file a Biologics License Application (BLA), with some of the funds going toward a commercial launch.
$112M: Series C for Radionuclide Therapies
AdvanCell announced the successful completion...
Today's Sponsors
Today's Sponsor